Additional Study Information: Weight gain after starting antiretroviral therapy (ART) is common, but recent studies have found that some people living with HIV (PLWH) who are taking an integrase strand transfer inhibitor (INSTI) combined with tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC) may gain more weight than people taking other drug combinations. A rising number of PLWH are overweight or obese. Higher body mass index and weight gain on ART increase the risk for diabetes, heart disease, and stroke. Researchers are looking to see if PLWH who have gained a significant amount of weight after starting or switching to an INSTI-containing regimen, can either reduce their rate of weight gain over time or even lose weight with a change to a different ART regimen. This study will include participants who are living with HIV-1, who have been virally suppressed for more than 48 weeks on a regimen consisting of an INSTI and TAF/FTC or TAF/3TC and who have experienced more than 10% weight gain since the initiation of this ART regimen.